Last updated: 2026-09-04 21:36:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Cybin Inc. (HELP) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $12.21, with a market capitalisation of $873.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.76 to $14.35. This page covers its latest market performance, valuation, price trends and company information.
$873.18M | |
$11.71 | |
$14.35 | |
$3.76 | |
$11.77 | |
980.76K | |
-- | |
-- | |
$14.35 | |
$3.76 | |
-- | |
-- |
Cybin Inc. (HELP) is trading at $12.28 in after-hours trading as of 2026-09-04 21:28:00, up 4.34% ($0.51) from the regular-session close of $11.77.
After-hours trading shows how investors are pricing HELP after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Cybin Inc. (HELP) moved from $11.97 to $12.21, representing a gain of 2.01% ($0.24).
The stock traded between $11.45 and $12.26 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.27 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 79.8%
HELP is currently trading at $12.21, placing it 79.8% of the way from its 52-week low of $3.76 to its 52-week high of $14.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
| Employees | 50 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cybin Inc. (HELP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.